Sanofi (NASDAQ: SNY) Reports Strong Q1 2026 Results Amidst Leadership Change

• Sanofi's first-quarter 2026 results significantly exceeded analyst expectations for both adjusted earnings and net sales.
• Revenue growth was primarily fueled by strong sales of its key drug Dupixent and successful new product launches.
• The company is undergoing a leadership transition with Belén Garijo appointed as Chief Executive Officer, signaling a new strategic phase.

Sanofi (NASDAQ: SNY) is a global pharmaceutical company that develops and distributes medicines and vaccines. With a market capitalization of approximately $110.98 billion, it is a major player in the healthcare industry. The stock currently trades at $46.08, with a 52-week range between $43.32 and $55.73.

On May 1, 2026, a Morgan Stanley analyst set a price target of $52.00 for Sanofi. This target represents a potential upside of about 12.85% from its trading price of $46.08. In the same action, the analyst downgraded the stock's rating from Overweight to Equal Weight.

This analysis follows Sanofi's strong first-quarter 2026 results. As highlighted by Zacks, the company reported adjusted earnings of $1.10 per share, which exceeded the consensus estimate of $1.06. Net sales for the quarter reached $12.3 billion, a 6.2% increase that also surpassed market expectations.

The company's growth was largely driven by its drug Dupixent, which saw sales climb 30.8% year-over-year. Revenue was further supported by new drugs, including Altuviiio and Ayvakit. On a regional basis, Sanofi experienced exceptional growth in the United States, with sales increasing by 26.2%.

The analyst rating adjustment also coincides with a leadership transition. As highlighted by GlobeNewswire, Belén Garijo was appointed Chief Executive Officer on May 1, 2026. The Board of Directors noted her appointment is intended to lead Sanofi in its next phase and strengthen its execution.